Objective: to analyze the efficacy and tolerability of the use of the drug Pravenor® Forte in patients with erectile dysfunction (ED) on the background of chronic prostatitis and prostatic hyperplasia (PH).
Materials and methods. The study involved 60 patients with ED who were divided into two groups. The majority of patients in both groups had chronic diseases. Patients of the main group (n = 30) received Pravenor® Forte 2 capsules per day for 30 days. Patients of the comparison group (n = 30) had ED correction without using the drug Pravenor® Forte. The diagnosis of ED was established by studying the anamnesis, objective clinical and laboratory and specialized examination.
Results. Prescription of the drug Pravenor® Forte significantly increased the indices of ICEF: erection achievement - by 89.4%, erection with sexual stimulation – 68.4%, and erection adequacy - by 66.7%. Erectile function increased by 86%, satisfaction with sexual intercourse by 84%, orgasm by 79.4%, libido by 84.9%, overall satisfaction by 50%. The patients of the comparison group had no significant change in ICEF parameters.
Conclusion. The drug Pravenor® Forte is effective, safe, convenient to use, which, combined with an affordable price, makes it advisable to prescribe it in ED therapy. Thanks to the multicomponent composition, Pravenor® Forte eliminates not only erectile dysfunction, but also symptoms of the inflammatory and dyshormonal genital diseases.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
Горпинченко И.И. Эректильная дисфункция: диагностика и современные методы лечения // Здоровье мужчины. – 2002. – No 1. – С. 9–11.
Горпинченко И.И. Лечение эректильной дисфункции. – К.: Профессионал, 2008. – 198 с.
Althof S.E., Corty E.W., Lewine S.B., tn al. EDITS: development of questionaries for evaluating satisfaction with treatments for erectile dysfunction. Urology 1999; 53,4:793–799.
Calabrт RS, Gervasi G, Bramanti P. LArginine and vascular diseases: lights and pitfalls! Acta Biomed. 2014 Dec 17;85(3):222–8.
Cui T, Kovell RC, Brooks DC, Terlecki RP. A Urologist’s Guide to Ingredients Found in TopSelling Nutraceuticals for Men’s Sexual Health. J Sex Med. 2015 Nov;12(11):2105–17.
Geppi-Attee S., Sultana S., Hodgson G. еt al. Duration of action of sildenafile citrate among men with erectile dysfunction of no organic cause. 9th World Meeting on Impotence, Perth, Western Australia, 2000. Int J Impot Res 2000; (suppl. 23): S21.
Lacchini R, Muniz JJ, Nobre YT. еt al. Relationship between Arginase 1 and Arginase 2 levels and genetic polymorphisms with erectile dysfunction. Nitric Oxide. 2015 Dec 1;51:36–42.
Melman A, Gingell JC. The epidemiology and pathophysiology of erectile dysfunction. J Urol. 1999 Jan;161(1):5–11.
Perez-Martinez C. Therapy with sildenafil for ED, why to wait one hour? 15th World Congress of Sexology 24 June, 2001 Abstract Book:182.
Rosen R.C., Riley A., Wagner G. et al. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction // Urology. – 1997. – V. 49. – P. 822–830.
Sachs B.D. Rats have «psychogenic» erections: a review of stimulus and neural control // J. of Impotence research. – 1996. – V. 8, No 3. – P. 136–136.
Roose S.P. Depression: links with ischemic heart disease and erectile dysfunction // J. Clin. Psychiatry. – 2003;64 Suppl. 10:26–30.
Safarinejad MR, Hosseini SY. Erectile dysfunction: clinical guidelines (2).Urol J. 2004 Fall;1(4):227–39.